drugset / Trial / NCT00682786
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.
Timeline
- Start
- 2002-10
- Primary completion
- 2008-12
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 225 mg/m2 | Intravenous |